SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 48,500 shares, a decline of 21.5% from the February 28th total of 61,800 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 75,800 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Investors Weigh In On SOPHiA GENETICS

Large investors have recently made changes to their positions in the company. Principal Financial Group Inc. lifted its stake in SOPHiA GENETICS by 6.3% in the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock valued at $5,290,000 after acquiring an additional 86,764 shares during the last quarter. Millennium Management LLC boosted its holdings in SOPHiA GENETICS by 6.5% in the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock worth $2,180,000 after purchasing an additional 42,689 shares in the last quarter. Federated Hermes Inc. increased its position in SOPHiA GENETICS by 40.5% during the fourth quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock worth $312,000 after buying an additional 28,819 shares during the last quarter. Green Alpha Advisors LLC raised its holdings in SOPHiA GENETICS by 119.3% during the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock valued at $145,000 after buying an additional 25,686 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter worth about $70,000. Institutional investors own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

SOPH has been the subject of a number of recent analyst reports. Craig Hallum initiated coverage on shares of SOPHiA GENETICS in a research note on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price objective for the company. BTIG Research set a $5.00 price target on SOPHiA GENETICS in a report on Thursday, March 6th.

SOPHiA GENETICS Stock Down 11.4 %

SOPH stock opened at $3.26 on Monday. The company has a 50 day moving average of $3.60 and a two-hundred day moving average of $3.49. The company has a market cap of $217.40 million, a price-to-earnings ratio of -2.99 and a beta of 1.01. SOPHiA GENETICS has a 12-month low of $2.70 and a 12-month high of $6.28. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The business had revenue of $17.73 million during the quarter, compared to analyst estimates of $17.71 million. On average, equities analysts anticipate that SOPHiA GENETICS will post -0.96 earnings per share for the current fiscal year.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.